BiomarkerBay has organized a symposium dedicated to the recent developments in the field of biomarker research for drug discovery. The afternoon symposium is held at Lab Central, in Boston, US, on 14 September, 2016.
The focus of the meeting is to explore the role and the latest advances of biomarker research in drug discovery and discuss about the challenges in the confirmation of newly-discovered biomarkers. The symposium has been organized by Ymke van der Geld and Martin Smit from the BiomarkerBay management board, Ep Oosting for ABL and Dawm Moore for QPS, representing the BiomarkerBay partners, in collaboration with Rudy Schreiber, from Suadeo-Consulting, and Walter de Wit, Julia Knoeff and Cato Bechtold from the Holland Innovation Network. A section of the symposium will be dedicated to the recent development in biomarker discovery for Alzheimer’s disease, with presentations by Steven Arnold, from Massachusetts General Hospital and Judith Steen, from The Boston Children’s hospital, who will present about emerging trends in biomarker research in Alzheimer’s disease. The symposium will end with a panel for discussion and time for networking and drinks.
For the full program, please visit the LabCentral site, here.
